International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
Concurrent chemoradiotherapy with helical tomotherapy for oropharyngeal cancer: a preliminary result.
To review the experience with and evaluate the treatment plan for helical tomotherapy for the treatment of oropharyngeal cancer. ⋯ Helical tomotherapy achieved encouraging clinical outcomes in patients with oropharyngeal carcinoma. Treatment toxicity was acceptable, even in the setting of concurrent chemotherapy. Long-term follow-up is needed to confirm these preliminary findings.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
Hypofractionated radiotherapy for favorable risk prostate cancer.
Since the recognition that prostate cancer probably has a low alpha/beta ratio, hypofractionated radiotherapy has become an attractive treatment option for localized prostate cancer. However, there is little experience with the use of hypofractionation delivering a high biologically equivalent dose. We report our experience with high-dose hypofractionated radiotherapy. ⋯ This hypofractionated regimen provides excellent biochemical control in favorable risk prostate cancer with an acceptable rate of late toxicity. Further studies exploring this hypofractionation regimen are warranted.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
RapidArc radiation therapy: first year experience at the University of Alabama at Birmingham.
To evaluate treatment planning and delivery for patients treated during our initial year of experience with RapidArc radiation therapy. ⋯ RapidArc plans have quality comparable to our standard SG-DMLC IMRT technique, and are delivered with similar accuracy in shorter time.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jul 2010
Multicenter StudyChemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide.
To evaluate the toxicity and efficacy of chemoradiotherapy with temozolomide (TMZ) administered in an intensified 1-week on/1-week off schedule plus indomethacin in patients with newly diagnosed glioblastoma. ⋯ The dose-dense regimen of TMZ administered in a 1-week on/1-week off schedule resulted in acceptable nonhematologic toxicity. Compared with data from the European Organization for Research and Treatment of Cancer/National Cancer Institute of Canada trial 26981-22981/CE.3, patients with an unmethylated MGMT gene promoter appeared not to benefit from intensifying the TMZ schedule regarding the median progression-free survival and overall survival. In contrast, data are promising for patients with a methylated MGMT promoter.
-
Int. J. Radiat. Oncol. Biol. Phys. · Jun 2010
Dose escalation of whole-brain radiotherapy for brain metastases from melanoma.
The majority of patients with brain metastases from melanoma receive whole-brain radiotherapy (WBRT). However, the results are poor. Hypofractionation regimens failed to improve the outcome of these patients. This study investigates a potential benefit from escalation of the WBRT dose beyond the "standard" regimen 30 Gy in 10 fractions (10x3 Gy). ⋯ Given the limitations of a retrospective study, the findings suggest that patients with brain metastases from melanoma receiving WBRT alone may benefit from dose escalation beyond 10x3 Gy. The hypothesis generated by this study must be confirmed in a randomized trial stratifying for significant prognostic factors.